Diltiazem Lannacher, 90 mg 20 pcs

Diltiazem Lannacher is antiarrhythmic, antihypertensive, vasodilator, antianginal.

Blocking calcium channels, reduces the flow of calcium ions into myocardial cells.

Causes dilatation of coronary arteries, thereby increasing coronary blood flow.

Creases tone of smooth muscle of peripheral arteries and RPS.

Indications

Active ingredient

Composition

Active ingredient:

diltiazem 0.09 g (90 mg);

Supplementary substances:

Lactose monohydrate,

Poly(ethylacrylate, methylacrylate),

Eudrajit NE30D,

methacrylic acid copolymer + Eudrajit L100-55,

poly(ethyl acrylate,

methyl methacrylate,

trimethylammonium methacrylate chloride),

Eudrajit RS PM,

hydroxypropyl methyl cellulose,

Magnesium stearate,

Polyethylene glycol,

Titanium dioxide,

Talc,

The anti-foaming agent SE2.

How to take, the dosage

The tablets should be taken before eating, without chewing and with a small amount of liquid.

The dosing regimen is determined individually.

There is usually a daily dose of 180-360 mg divided into 2 doses.

The dose of the drug may be reduced to 180 mg once daily, in the morning, when changing to long-term maintenance therapy.

Interaction

Potentially dangerous are combinations with beta-adrenoblockers, quinidine and other class Ia antiarrhythmic drugs, cardiac glycosides (excessive bradycardia, delayed AV conduction, reduced myocardial contractility with the development of signs of CH).

Procainamide, quinidine, etc. Drugs that cause Q-T interval prolongation increase the risk of significant Q-T interval prolongation. May increase the bioavailability of propranololol. Drugs for inhalation anesthesia (hydrocarbon derivatives), thiazide diuretics, etc. Drugs that reduce BP, increase the hypotensive effect of diltiazem.

Cimetidine increases concentration of diltiazem in blood; phenobarbital, diazepam, rifampicin decrease it. Increases blood concentrations of cyclosporine, carbamazepine, theophylline, quinidine, valproic acid and digoxin (dose reduction may be required). Concomitant administration of nitrates (including prolonged forms) is possible. Increases the cardiodepressant effect of general anesthetics.

Li+ drugs may increase the neurotoxic effects of diltiazem (nausea, vomiting, diarrhea, ataxia, tremor and/or tinnitus). Indomethacin (and other NSAIDs), GCS and estrogens, and sympathomimetic drugs reduce the hypotensive effect.

Special Instructions

Diltiazem Lannacher is used with caution in AV blockade of degree I, intraventricular conduction disorders, patients prone to arterial hypotension, chronic heart failure, myocardial infarction with left ventricular failure, ventricular tachycardia with dilation of ORS complex, liver failure, renal failure, elderly patients, children (effectiveness and safety of use are not studied).

Contraindications

Side effects

Nervous system and sensory organs: Headache, dizziness, fainting, increased fatigue, asthenia, sleep disturbances, somnolence, anxiety, extrapyramidal (parkinsonism) disorders (ataxia, masked face, shuffling gait, stiffness of hands or feet, trembling hands and fingers, difficulty swallowing), depression; when used in high doses – paresthesias, tremor, visual disturbances (transient vision loss).

Cardiovascular system: asymptomatic decrease of BP; rarely – angina pectoris, arrhythmia (including torsade de pointes and ventricular fibrillation), bradycardia (less than 50 bpm) or tachycardia, AV class II-III blockade. up to asystole, development or worsening of heart failure; when used in high doses and by IV administration – angina pectoris, bradycardia, AV block, marked BP decrease, worsening of chronic heart failure.

Digestive system disorders: dry mouth, increased appetite, nausea, vomiting, constipation or diarrhea, increased liver transaminase activity, gum hyperplasia (bleeding, painfulness, swelling).

With the hematopoietic system: rare – thrombocytopenia, agranulocytosis.

Overdose

Symptoms

Bradycardia, atrioventricular conduction disorders, arterial hypotension.

Treatment:

Depending on the severity of overdose manifestations.

Gastric lavage is necessary, activated charcoal is prescribed, further treatment is symptomatic.

If necessary, atropine, isoproterenol, dopamine or dobutamine should be prescribed and, if conduction abnormalities are pronounced, electrocardiostimulation may be used.

Similarities